Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA – 2009 protocol

Rocha, Juliana Maria Camargos; Xavier, Sandra Guerra; Souza, Marcelo Eduardo de Lima; Murao, Mitiko; Oliveira, Benigna Maria de

doi:10.1080/08880018.2019.1636168

Cited by 5 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of MRD was only evaluated on day 15 of the induction phase of the protocol. It is known that MRD is a strong prognostic factor for determining risk groups and subsequently the intensity of post-induction therapy (from significant treatment reduction to mild or strong intensification) 5,[8][9][10][11] . The technologies of MRD measurement for childhood ALL studies are based on molecular or flow cytometry, and the use of these methods depends on the resources available.…”

Section: Discussionmentioning

confidence: 99%

Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia

Zawitkowska

Lejman

Romiszewski

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The aim of the study was to retrospectively compare the effectiveness of the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols and the distribution of risk groups by the two protocols after minimal residual disease (MRD) measurement as well as its impact on survival. We reviewed the medical records of 3248 patients aged 1–18 years with newly diagnosed ALL who were treated in 14 hemato-oncological centers between 2002 and 2018 in Poland. The overall survival (OS) of 1872 children with ALL treated with the ALL IC 2002 protocol was 84% after 3 years, whereas the OS of 1376 children with ALL treated with the ALL IC 2009 protocol was 87% (P < 0.001). The corresponding event-free survival rates were 82% and 84% (P = 0.006). Our study shows that the ALL IC-BFM 2009 protocol improved the results of children with ALL compared to the ALL IC-BFM 2002 protocol in Poland. This analysis confirms that MRD marrow assessment on day 15 of treatment by FCM-MRD is an important predictive factor.

show abstract

Section: Discussionmentioning

confidence: 99%

Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia

Zawitkowska

Lejman

Romiszewski

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, the cure rate of ALL in children (defined as disease-free survival for more than 10 years) can reach as high as 80%, which is related to stratified therapy based on the risk of relapse, and biological characteristics of leukemia cells, increasingly excellent supportive treatment and communication, and the optimization of treatment regimens by cooperative research at home and abroad. [ 8 , 9 ] Among them, according to morphology, immunology, cytogenetics, molecular biology, early treatment response, and other risk factors, the risk classification of ALL children with corresponding stratified chemotherapy provided have got more importance, and attention from clinicians increasingly. [ 10 ]…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia

et al. 2020

View full text Add to dashboard Cite

Background: To systematic review the efficacy and safety of 6-thioguanine (6-TG) in the substitute of 6-mercaptopurine (6-MP) in the treatment for patients with childhood acute lymphoblastic leukemia (ALL) in the maintenance phase, and to explore its clinical application value. It provides theoretical guidance for the maintenance treatment of ALL in children from the perspective of evidence-based medicine. Methods: By means of computer retrieval, Chinese databases were searched: Chinese Biomedical Database (CBM), China national knowledge internet (CNKI), Chongqing Weipu Database (VIP), and Wanfang Database; Foreign databases: PubMed, The Cochrane Library, Embase, and Web of Science were applied to find out randomized controlled trial (RCT) for 6-TG in childhood acute lymphoblastic leukemia. By manual retrieval, documents without electronic edition and related conference papers were retrieved. The retrieval time ranges from the beginning of the establishment of the databases to September 1st, 2019. According to the inclusion, and exclusion criteria by 3 researchers, the literature screening, data extraction, and research methodological quality evaluation were completed. RevMan 5.3 software was applied to evaluate the quality of the included literature, and Stata 12.0 software was used to conduct meta-analysis of the outcome indicators of the included literature. Results: This study systematically evaluated the efficacy and safety of 6-TG in the substitute of 6-MP as a maintenance drug for childhood acute lymphoblastic leukemia. Through the key outcome indicators, this study is expected to draw a scientific, practical conclusion for 6-TG in the treatment of childhood acute lymphoblastic leukemia. This conclusion will provide evidence-based medical direction for clinical treatment. Conclusion: The efficacy and safety of 6-TG in the substitute of 6-MP in the maintenance treatment of childhood acute lymphoblastic leukemia will be confirmed through this study. The conclusions will be published in relevant academic journals. Registration: PROSPERO (registration number is CRD42020150466).

show abstract

“…[10][11][12] Therefore, we assessed the prognostic impact of IKZF1 deletions in ETV6::RUNX1-and HeHpositive ALL by evaluating previously published data from 16 international trials. 19,[21][22][23][24][25][26][27][28][29][30][31][32]…”

Section: Introductionmentioning

confidence: 99%

“…Because of the rarity of IKZF1 deletions within the subset of patients with favorable cytogenetics, its prognostic effect remains unclear 10–12 . Therefore, we assessed the prognostic impact of IKZF1 deletions in ETV6 :: RUNX1 ‐ and HeH‐positive ALL by evaluating previously published data from 16 international trials 19,21–32 …”

Section: Introductionmentioning

confidence: 99%

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

et al. 2023

View full text Add to dashboard Cite

IKZF1 deletions are an established prognostic factor in childhood acute lymphoblastic leukemia (ALL). However, their relevance in patients with good risk genetics, namely ETV6::RUNX1 and high hyperdiploid (HeH), ALL remains unclear. We assessed the prognostic impact of IKZF1 deletions in 939 ETV6::RUNX1 and 968 HeH ALL patients by evaluating data from 16 trials from 9 study groups. Only 3% of ETV6::RUNX1 cases (n = 26) were IKZF1-deleted; this adversely affected survival combining all trials (5-year event-free survival [EFS], 79% versus 92%; P = 0.02). No relapses occurred among the 14 patients with an IKZF1 deletion treated on a minimal residual disease (MRD)-guided protocols. Nine percent of HeH cases (n = 85) had an IKZF1 deletion; this adversely affected survival in all trials (5-year EFS, 76% versus 89%; P = 0.006) and in MRD-guided protocols (73% versus 88%; P = 0.004). HeH cases with an IKZF1 deletion had significantly higher end of induction MRD values (P = 0.03). Multivariate Cox regression showed that IKZF1 deletions negatively affected survival independent of sex, age, and white blood cell count at diagnosis in HeH ALL (hazard ratio of relapse rate [95% confidence interval]: 2.48 [1.32-4.66]). There was no evidence to suggest that IKZF1 deletions affected outcome in the small number of ETV6::RUNX1 cases in MRD-guided protocols but that they are related to higher MRD values, higher relapse, and lower survival rates in HeH ALL. Future trials are needed to study whether stratifying by MRD is adequate for HeH patients or additional risk stratification is necessary.

show abstract

Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA – 2009 protocol

Cited by 5 publications

References 43 publications

Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia

Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia

Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About